一分钟看懂
这是一项关于黑色素瘤的II 期研究，登记的药物或干预包括Pembrolizumab；Aldesleukin，当前状态为招募中。登记地点显示中国Bethesda有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Pembrolizumab；Aldesleukin · II 期
登记条件中文摘要
登记的基本范围为不限性别，年龄18 岁至120 岁；另列出8项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- National Institutes of Health Clinical Center · Bethesda
公开的入选条件
- * Participants must have histologically or cytologically confirmed cancer that falls into one of three cohorts: (1) metastatic melanoma or advanced locoregional melanoma not amenable to curative surgical resection and refractory to anti-PD-1 therapy; (2) metas
- * Participants must have measurable disease (per RECIST v1.1 criteria), metastatic melanoma or renal cell cancer.
- * Age \>=18 years of age.
- * Clinical performance status of ECOG 0 or 1.
- * Willing to practice birth control from the time of enrollment on this study and for four months after treatment.
- * Must have a negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus.
- * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Participants who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatme
- * Seronegative for hepatitis B antigen and for hepatitis C antibody. If hepatitis C antibody test is positive, then participant must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05155033；登记信息更新于 2026-10-02。